Home Based Infusions for Ocrelizumab
Key facts
- Where
- Centennial, United StatesSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT04650321, who can take part
Where in United States
- AmeritaCentennial, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Colorado, Denver
- Trial code
- NCT04650321
- Record updated
- 10 June 2021
- Original description
The goal is to assess the safety and effectiveness of home ocrelizumab infusion.Read full original descriptionShow less
Evaluating the Feasibility of Pandemic Forward, Telehealth Based Home Based Infusions
The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
Inclusion: Current active patient of Rocky Mountain MS Center at the time of final study consent; Between 18-55 years of age at the time of final study consent; Diagnosis of primary progressive or relapsing MS as defined by the 2017 McDonald criteria.19; Has at minimum completed their first 600 mg dose of ocrelizumab; Is physically residing in the Denver metro, Fort Collins or Colorado Springs area at the time of final study consent; Has a Patient Determined Disease Steps (PDDS) between 0 to 6.5 20; Can complete patient reported outcomes developed and validated as English written scales; Must be able and willing to give meaningful, informed consent via electronic signature prior to participation in the study, in accordance with local and FDA regulatory requirements; Whose treating neurologist at the RMMSC feels that continuing ocrelizumab s medically appropriate based on at the time of final study consent.
Exclusion: Has previously not participated in the SaROD trial at the RMMSC site; Any of the following abnormal laboratory results as processed by a University of Colorado Hospital laboratory site and deemed clinically inappropriate to proceed with a home infusion by the treating neurologist at RMMSC; Not pregnant, intentions to get pregnant or lactating at the time of final study consent and on the day of infusion.